Why BayImmuNet?

• Immunotherapy – therapeutic influencing of the human immune system – is one of the most important cornerstones of modern medical research. One of the current challenges is the translation of innovative therapy approaches from the laboratory into clinical application.
• In the area of Immunotherapy – particularly antibody therapy and cellular therapy – Bavaria has excellent scientific teams and, consequently, a high degree of scientific potential. Many of the projects carried out by those teams are already at a stage in which rapid translation into clinical application can be expected.
• However, on the part of the university hospitals there is an investment bottleneck due to the Medical Preparations Act that is preventing rapid and efficient translation into clinical application.
• BayImmuNet, a unique network established in Germany in 2008, has set itself the goal of achieving faster translation of new approaches in immunotherapy into clinical application.

Our Motto is:

„Collaborate in research! Share knowledge!
Conquer disease!“

 

Thus, it is our common goal to …

• intensify the collaboration of academic centres and to promote partnerships with pharmaceutical and biotech companies.
• accelerate the transfer of research findings into early clinical trials (“translational medicine”).
• develop therapeutic reagents suited for clinical applications.

 

How will we achieve this?

• We support renowned scientists in the field of translational immunotherapy in Bavaria by financing research groups.
• We provide financial support for talented young scientists who contribute to the development of new therapies.
• We facilitate collaborations between scientists and research centres in Bavaria through the exchange of know-how and technologies, joint clinical studies, open access to specialized laboratory facilities, etc.
• We promote joint ventures between science and business to accelerate the transfer of research findings into clinical practice on the basis of mutual cooperation agreements.